NCT06783153

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.

Conditions

• Radiotherapy Induced Diarrhea
• Acute Radiation Enteritis
• Prostate Cancer
• Cervical Adenocarcinoma
• Bladder (Urothelial, Transitional Cell) Cancer
• Rectal Adenocarcinoma
• Pelvic Radiotherapy
• Rifaximin

Interventions

Type	Name	Description
DRUG	Rifaximin 550 MG	Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
DRUG	Standard Care Chemoradiation	Patients will receive standard chemotherapy and/or radiation

Timeline

• Start date: 2025-01-20
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2025-01-20
• Last updated: 2025-01-20

Locations

1 site across 1 country: Egypt